10x Genomics v Vizgen (CFI, ORD_49363/2024, 24 October 2024)
| Date | 24 October 2024 |
|---|---|
| Court | CFI |
| Division | Hamburg (DE) Local Division |
| Type of action | Application RoP262A |
| Registry reference | App_49295/2024 · ORD_49363/2024 |
| Parties | 10x Genomics, Inc., President and Fellows of Harvard College v. Vizgen, Inc. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By order of 24 October 2024 (UPC_CFI_22/2023, ACT_460565/2023, ORD_49363/2024), the judge-rapporteur of the Hamburg Local Division (S. Klepsch), in the infringement action on EP 4 108 782 brought by 10x Genomics and President and Fellows of Harvard College against Vizgen, restricted access to a licence agreement filed as exhibit BP 34 to the parties’ outside counsel and their staff. The Registry published it under two entries.
Question
May access to confidential information be denied to every natural person of the opposing party, although Rule 262A.6 RoP in principle requires access for at least one person per party?
Decision
Trade secret status need not be established with certainty: it is enough that it is more likely than not, and Vizgen did not dispute that the agreement was confidential. Rule 262A.6 RoP requires access for at least one natural person per party, unless the parties agree to restrict access to outside counsel. Here the parties had agreed by emails in June 2024 to a regime comparable to the protective order in the parallel action before the District of Delaware. The equal treatment argument based on the wider access regime for the licence filed by Vizgen does not undo that agreement. The information may not be used outside the proceedings, even after they end, and any breach may lead to a penalty payment. The order is not appealable and leave to appeal is not granted of the court’s own motion (Rule 220 RoP).
Key points for practice
- Practical point: an agreement, even by email, on an outside attorneys’ eyes only regime displaces the minimum access of one person per party under Rule 262A.6 RoP, its reach should be weighed before it is given.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 58
- Rules of Procedure
- Rules 220, 262A, 331.1, 334 and 335
- Other provisions
- Directive (EU) 2016/943, Arts. 2 and 9
- Case law cited
- Plant-e v Arkyne, The Hague Local Division, 4 March 2024, 10x Genomics v Vizgen, Hamburg Local Division, 15 August 2024
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Decisions in the same proceedings
Going further
Lexicon: Confidentiality club.
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimant10x Genomics, Inc.57 decisions in the corpusFollow this party
- claimantPresident and Fellows of Harvard College29 decisions in the corpusFollow this party
- defendantVizgen, Inc.6 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application RoP262A
- Outcome (Dhenne Avocats summary)
- Le contrat de licence produit par les demanderesses est déclaré confidentiel et son accès réservé aux avocats des parties et à leurs secrétariats, les parties étant convenues d'un tel régime.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 108 782mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- 10x Genomics v Vizgen (CFI, ORD_58030/2024, 24 October 2024) cited in this record
- 10x Genomics v Vizgen (CFI, 15 August 2024) cited in this record
- Plant-e v Arkyne (CFI, 4 March 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 108 782Compositions and methods for analyte detection recorded proprietor: Harvard University | Mentioned in the analysis (role not qualified) Also mentioned in 18 other decision(s): NanoString Technologies v 10x Genomics (CoA, 11 March 2024) · 10x Genomics v NanoString (CFI, 19 September 2023) · 10x Genomics v Bruker Spatial Biology (CFI, 11 April 2025) · 10x Genomics v Vizgen (CoA, 11 March 2025) · 10x Genomics v Vizgen (CoA, 5 March 2025) · 10x Genomics v Vizgen (CFI, 20 December 2024) · NanoString Technologies v 10x Genomics (CoA, 10 December 2024) · 10x Genomics v Vizgen (CFI, 1 November 2024) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.